Suggested remit: To appraise the clinical and cost effectiveness of dostarlimab within its marketing authorisation for treating previously treated advanced and recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency.
Status In progress
Process STA 2018
ID number 3802

Provisional Schedule

Committee meeting: 1 07 September 2021

Project Team

Project lead Michelle Adhemar

Email enquiries

Evidence Review Group / Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick


Companies sponsors GlaxoSmithKline (dostarlimab)
Others Department of Health and Social Care
  NHS England
  NHS Richmond CCG
  NHS South East Staffordshire & Seisdon Peninsular
  Welsh Government
Patient carer groups Black Health Agency
  Cancer Black Care
  Cancer Equality
  Cancer 52
  Endometriosis UK
  Eve Appeal
  Go Girls
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Jo’s Cervical Cancer Trust
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  Wellbeing of Women
Professional groups Association of Cancer Physicians
  Association of Surgeons of Great Britain and Ireland
  British Association of Surgical Oncology
  British Geriatrics Society
  British Gynaecological Cancer Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Society for Clinical Cytology
  British Society for Colposcopy and Cervical Pathology
  Cancer Research UK
  National Forum of Gynaecological Oncology Nurses
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Obstetricians & Gynaecologists
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Oncology Nursing Society


Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (carboplatin, doxorubicin, paclitaxel)
  Bausch and Lomb UK (megestrol)
  Janssen-Cilag (doxorubicin)
  Hospira UK (carboplatin, paclitaxel)
  Medac GmbH (doxorubicin)
  Pfizer (doxorubicin, medroxyprogesterone acetate)
  Seacross Pharmaceuticals (doxorubicin, paclitaxel)
General commentators Allied Health Professionals Federation
  All Wales Therapeutics and Toxicology Centre
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Gynaecological Cancer Group
  Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research
  Peaches Womb Cancer Trust


Key events during the development of the guidance:

Date Update
14 January 2021 Invitation to participate
01 October 2020 - 29 October 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
15 October 2020 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance